Skip to main content
Clinical Trials/NCT06516016
NCT06516016
Not yet recruiting
Not Applicable

Multimodal Markers of Neurodegenerative Disorders at Presymptomatic Stages

Paris Brain Institute (ICM)1 site in 1 country1,000 target enrollmentSeptember 1, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Neurodegenerative Diseases
Sponsor
Paris Brain Institute (ICM)
Enrollment
1000
Locations
1
Primary Endpoint
Rate of change of clinical, neurophysiological, anatomical and molecular marker profiles of neurodegenerescence and neuroinflammation in presymptomatic individuals
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

NeuroPrems is a prospective, monocentric, longitudinal, not relating to a medicinal product for human use, non-randomized, non-controlled research. The study mainly aims to identify longitudinal changes and events in multimodal markers of neurodegeneration and neuroinflammation during the presymptomatic phases of neurodegenerative diseases.

Registry
clinicaltrials.gov
Start Date
September 1, 2024
End Date
August 31, 2034
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Paris Brain Institute (ICM)
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Rate of change of clinical, neurophysiological, anatomical and molecular marker profiles of neurodegenerescence and neuroinflammation in presymptomatic individuals

Time Frame: Baseline, Year 1, Year 2, Year 3, Year 4 and Year 5

Clinical markers will be: neurological and neuropsychological testing, and questionnaires; Neurophysiological markers will link functional brain networks and cognitive processes by using MEG, kinematic or eye movement recordings; Anatomical markers will be: cerebral MRI, glymphatic imaging, PET and skin elasticity; Molecular markers will be: blood, CSF, skin cells, iPSC derived biomarkers, transcriptomic, proteomic and metabolomic signatures

Secondary Outcomes

  • Mean time of onset in genetically presymptomatic individuals(Baseline, Year 1, Year 2, Year 3, Year 4 and Year 5)
  • Rate of change in consumption of information issued from Consultations, hospitalizations and medication prescriptions(From Year -10 to Year 10 (annual update))
  • Time to loss of autonomy(Baseline, Year 1, Year 2, Year 3, Year 4 and Year 5)
  • Rate and mean time to symptomatic conversion/progression(Baseline, Year 1, Year 2, Year 3, Year 4 and Year 5)
  • Intra-individual change in trajectory profiles determined by multimodal analysis(Baseline, Year 1, Year 2, Year 3, Year 4 and Year 5)
  • Rate of change for each study marker(Baseline, Year 1, Year 2, Year 3, Year 4 and Year 5)
  • Rate of change in the self-administered questionnaires(Baseline, Year 1, Year 2, Year 3, Year 4 and Year 5)

Study Sites (1)

Loading locations...

Similar Trials